Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer

Gillessen Sommer, Silke (Participant)

Division of Cancer Sciences (L5)

Impact: Health impacts

Public summary

The study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radium-223.

Impact date	2016
Category of impact	Health impacts
Impact level	Benefit

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer

Public summary

Related content

Research output

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial